Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 160
- 试验地点
- 1
- 主要终点
- miRNA expression profile as measured by miRNA array
研究概览
简要总结
Epithelial ovarian cancer is the most lethal gynecological malignancy in developed countries and the fifth most common cause of cancer-related death in women. Poor prognosis is due to challenges in early diagnosis and development of inevitable resistance to chemotherapy in majority of patients despite of good initial treatment response. The purpose of this prospective study is to analyze variation in microRNA expression in prediction of primary treatment response and the role of microRNAs in development of chemoresistance in epithelial ovarian cancer.
• Objectives: To screen microRNAs from prospectively collected plasma, urine and tumor samples from patients diagnosed with epithelial ovarian cancer. Samples are analyzed for microRNA expression and differential expression is correlated with primary treatment response, progression-free survival and overall survival.
• Methods: Plasma, urine and tumor samples are collected at primary surgery (open surgery or diagnostic laparoscopy) or interval debulking surgery, at 1st, 3rd and 6th neoadjuvant or adjuvant chemotherapy and at progression for high-throughput screening of microRNA expression by array technology.
详细描述
Inclusion criteria:
patients operated for a suspected ovarian malignancy in the Department of Obstetrics and Gynecology in Tampere University Informed consent obtained
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •18 years of age, informed consent.
排除标准
- •Informed consent not provided, age under 18 years.
结局指标
主要结局
miRNA expression profile as measured by miRNA array
时间窗: 5 years
Expression profile calculated with bioinformatical analysis
次要结局
- Progression-free survival(5 years)
- Over-all survival(5 years)
研究者
Annika Auranen
Chief in gynecological oncology
Tampere University Hospital
